Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Septerna, Inc. (NASDAQ:SEPN) has earned an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $52.4444.

A number of equities analysts have recently weighed in on SEPN shares. Truist Financial lifted their price target on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. JPMorgan Chase & Co. upped their price objective on shares of Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a research report on Wednesday. JonesTrading raised their price objective on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. HC Wainwright lifted their target price on Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a research note on Tuesday, August 11th.

Septerna Price Performance

Shares of SEPN stock opened at $40.00 on Friday. The stock has a market cap of $1.87 billion, a PE ratio of -74.07 and a beta of 2.29. The stock has a 50-day moving average of $36.85 and a 200-day moving average of $30.28. Septerna has a one year low of $11.70 and a one year high of $51.10.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.14. The business had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. As a group, research analysts anticipate that Septerna will post -1.36 earnings per share for the current year.

Insider Activity

In related news, COO Elizabeth Bhatt sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $7,665,196. The trade was a 12.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Daniel D. Long sold 15,000 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total value of $532,650.00. Following the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at approximately $3,423,590.12. The trade was a 13.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 72,828 shares of company stock worth $2,684,314 in the last 90 days. Corporate insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. TRV GP V LLC acquired a new position in Septerna in the 2nd quarter worth $208,160,143,000. TRV GP VI LLC acquired a new stake in shares of Septerna in the 2nd quarter valued at about $141,048,460,000. BlackRock Inc. bought a new stake in shares of Septerna in the second quarter valued at about $64,706,000. Jupiter Topco LLC bought a new stake in shares of Septerna in the second quarter valued at about $43,723,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Septerna by 86.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after buying an additional 1,260,409 shares during the period.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.